renal cell carcinoma

News

Scotland backs three new uses for MSD's Keytruda

Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD's Keytruda in combination with Eisai's Lenvima as a treatment for advanced or recurrent

News

Routine NHS access to Ibrance assured with new NICE guidance

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui

News

BMS' plan to move Opdivo into adjuvant RCC gets knocked back

Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), th

News

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.<

News

Merck gets EU nod for Keytruda in adjuvant kidney cancer

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug

Patients